Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 365-371

  Klintman, Marie ^a   Würtz, Sidse Ørnbjerg ^b   Christensen, Ib Jarle ^c   Hertel, Pernille Bræmer ^b   Fernö, Mårten ^a   Malmberg, Martin ^a   Mouridsen, Henning ^d   Cold, Frederik ^e   Schrohl, Anne Sofie ^b   Foekens, John A ^f   Malmström, Per ^a   Brünner, Nils ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FINSEN LABORATORY   (Denmark)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Breast cancer resistance; Chemotherapy; Predictive marker; TIMP 1; Tumor extracts

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; NAVELBINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; DISEASE FREE SURVIVAL; DRUG RESPONSE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SWEDEN;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77953020152     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0483-1     Document Type: Article

References (24)

1. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 16:1569-1583
2. Thomssen C, Janicke F (2000) Do we need better prognostic factors in node-negative breast cancer? Eur J Cancer 36:293-298
3. Goldhirsch A, Coates AS, Gelber RD et al (2006) First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17:1772-1776
4. Knoop AS, Knudsen H, Balslev E et al (2005) Retrospective analysis of topoisomerase IIα amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23:7483-7490
5. Nielsen KV, Ejlertsen B, Jørgensen JT, Knoop A et al (2008) The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 47:725-734 (Pubitemid 351878451)
6. Arriola E, Rodriguez-Pinilla SM, Lambros MBK et al (2007) Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 106:181-189 (Pubitemid 350045015)
7. Ree AH, Florenes VA, Berg JP et al (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3:1623-1628
8. McCarthy K, Maguire T, McGreal G et al (1999) High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 84:44-48 (Pubitemid 29059107)
9. Schrohl AS, Christensen IJ, Pedersen AN et al (2003) Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2:164-172
10. Schrohl AS, Holten-Andersen MN, Peters HA et al (2004) Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10:2289-2298
11. Würtz SØ, Møller S, Mouridsen H et al (2008) Plasma and serum levels of tissue inhibitor of metalloprrteinases-1 are associated with prognosis in node-negative breast cancer - a prospective study. Mol Cell Proteomics 7:424-430 (Pubitemid 351298453)
12. Lipton A, Suhail MA, Leitzel K et al (2007) Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 109:1933-1939 (Pubitemid 46744185)
13. Lipton A, Leitzel K, Chaudri-Ross HA et al (2008) Serum TIMP1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 26(16):2653-2658
14. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN et al (2006) Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 12:7054-7058
15. Willemoe GL, Hertel PB, Bartels A et al (2009) Lack of TIMP-1 tumor cell immunoreactivity predicts effect of adjuvant anthracycline based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. Eur J Cancer, doi : 10.1016/j.ejca.2009.05.029
16. Davidsen ML, Würtz SO, Romer MU et al (2006) TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapyinduced apoptosis. Br J Cancer 95:1114-1120
17. LiG,FridmanR,KimHR(1999)Tissueinhibitorofmetalloproteinase- 1inhibitsapoptosisofhumanbreastepithelialcells.CancerRes59:6267- 6275(Pubitemid30035652)
18. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Clin Oncol 23:9067-9072
19. Pedersen AN, Christensen IJ, Stephens RW (2000) The complex between urokinase and its inhibitor in primary breast cancer, relation to survival. Cancer Res 60:6927-6934
20. Ejlertsen B, Mouridsen HT, Langkjer ST et al (2004) Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 22:2313-2320 (Pubitemid 41115387)
21. World Health Organization (1979) WHO handbook for reporting results for cancer treatment. World Health Organization Offset Publications No. 48, Geneva
22. Holten-Andersen MN, Murphy G, Nielsen HJ et al (1999) Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 80:495-503
23. Sørensen NM, Byström P, Christensen IJ et al (2007) TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13:4117-4122
24. Würtz SO, Schrohl A, Brünner N, Lademann U (2009) Tissue inhibitor of metalloproteinases-1 protects the human breast carcinoma cell line MCF-7 S1 against anthracycline-induced cell death by activation of the akt survival pathway [abstract]. Cancer Res69(Suppl):161s